Shield Therapeutics plc
Warrant Exercise and Expiry
("Shield" or the "Company" or the "Group")
London, UK, 3 July 2017: Shield Therapeutics (LSE: STX), the specialty pharmaceutical company focused on secondary care, is pleased to provide an update on the further exercise of the Company's warrants prior to their expiry on 30 June 2017 (the "Warrants").
In addition to the Warrants exercised as part of the Fundraise, the shares in respect of which were admitted to trading on 28 June 2017, the Company has received further warrant exercise notices in respect of a 323,230 Warrants, for aggregate gross subscription proceeds of £484,845. Application has been made for the 323,230 new ordinary shares to be issued in respect of these Warrants to be admitted to trading on the AIM market of the London Stock Exchange on 7 July 2017.
As a result of the Fundraise and the additional Warrants exercised (as set out in this announcement), an aggregate gross proceeds of £12.45 million has been raised by the Company.
For the avoidance of doubt, the 4,472,892 unexercised Warrants as at close of business on 30 June 2017 have now expired in accordance with the terms of the Warrant instrument and the Warrant has been removed from trading on the AIM market.
The Company does not hold any shares in treasury. Therefore, following admission of the new ordinary shares, there will be 116,425,851 ordinary shares in issue. This figure should be used by shareholders as the denominator for the calculations by which they may determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
Notes
All defined terms used in this announcement shall have the same meaning as defined in the Company's announcement published on 15 June 2017.
Enquiries
Shield Therapeutics plc |
+44 (0)20 7186 8500 |
Carl Sterritt, Chief Executive Officer Joanne Estell, Chief Financial Officer Karl Keegan, Director Corporate Development |
|
Nominated Adviser, Joint Bookrunner and Joint Broker |
|
+44 (0)20 3100 2222 |
Liberum Capital Limited |
|
Christopher Britton Steve Pearce Jonathan Wilkes-Green |
Joint Bookrunner and Joint Broker |
|
+44 (0)20 7418 8900 |
Peel Hunt LLP |
|
|
James Steel Alastair Rae |
Oliver Jackson |
|
|
Financial PR Advisor |
+44 (0) 203 709 5700 |
Consilium Strategic Communications |
|
Mary-Jane Elliott Matthew Neal |
|
About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD) which has exclusive IP rights until the mid-2030's. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtx.com
